Choice of Treatment Regimen as Add-On to Insulin in Japanese Patients with Type 2 Diabetes Mellitus: Physicians’ Perspective in a Real-World Setting, Insight from a Web Survey

[1] Morimoto A(2013)Impact of impaired insulin secretion and insulin resistance on the incidence of type 2 diabetes mellitus in a Japanese population: the Saku study Diabetologia 56 1671-1679

[2] Tatsumi Y(2004)Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes Diabetes Res Clin Pract 66 S37-S43

[3] Deura K(2015)Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetologia 58 429-442

[4] Fukushima M(2013)Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes J Clin Endocrinol Metab 98 668-677

[5] Suzuki H(2015)Efficacy and safety of sitagliptin added to insulin in Japanese patients with type 2 diabetes: the EDIT randomized trial PLoS ONE 10 e0121988-269

[6] Seino Y(2016)Comparison of clinical characteristics in patients with type 2 diabetes among whom different antihyperglycemic agents were prescribed as monotherapy or combination therapy by diabetes specialists J Diabetes Investig. 7 260-359

[7] Inzucchi SE(2015)Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents Diabetes Res Clin Pract 108 350-817

[8] Bergenstal RM(2015)Use of oral combination therapy for type 2 diabetes in primary care: meeting individualized patient goals Postgrad Med 127 808-708

[9] Buse JB(2013)Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis Diabetologia 56 696-818

[10] Currie CJ(2014)Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes Diabetes Obes Metab 16 812-1099

[1] Morimoto A(2013)Impact of impaired insulin secretion and insulin resistance on the incidence of type 2 diabetes mellitus in a Japanese population: the Saku study Diabetologia 56 1671-1679

[2] Tatsumi Y(2004)Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes Diabetes Res Clin Pract 66 S37-S43

[3] Deura K(2015)Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetologia 58 429-442

[4] Fukushima M(2013)Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes J Clin Endocrinol Metab 98 668-677

[5] Suzuki H(2015)Efficacy and safety of sitagliptin added to insulin in Japanese patients with type 2 diabetes: the EDIT randomized trial PLoS ONE 10 e0121988-269

[6] Seino Y(2016)Comparison of clinical characteristics in patients with type 2 diabetes among whom different antihyperglycemic agents were prescribed as monotherapy or combination therapy by diabetes specialists J Diabetes Investig. 7 260-359

[7] Inzucchi SE(2015)Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents Diabetes Res Clin Pract 108 350-817

[8] Bergenstal RM(2015)Use of oral combination therapy for type 2 diabetes in primary care: meeting individualized patient goals Postgrad Med 127 808-708

[9] Buse JB(2013)Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis Diabetologia 56 696-818

[10] Currie CJ(2014)Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes Diabetes Obes Metab 16 812-1099